ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

COG Cambridge Cognition Holdings Plc

56.20
1.20 (2.18%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cambridge Cognition Holdings Plc LSE:COG London Ordinary Share GB00B8DV9647 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.20 2.18% 56.20 54.00 55.00 54.50 54.50 54.50 21,504 16:35:07
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 12.61M -409k -0.0117 -46.58 18.99M

Cambridge Cognition Holdings PLC New digital health contract worth over GBP700,000

21/12/2020 7:00am

RNS Non-Regulatory


TIDMCOG

Cambridge Cognition Holdings PLC

21 December 2020

Cambridge Cognition Holdings Plc

   (" Cambridge Cognition"   or the "Company") 

Cambridge Cognition wins new digital health contract worth over GBP700,000

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has won a new contract with a major pharmaceutical client to provide digital assessments of mood and cognition for a depression trial. The contract is worth over GBP700,000 with most of the revenue expected to be recognised in 2021.

Impairments in cognition can persist after recovery from a period of depression and this can contribute to difficulties in reaching a full recovery. So, in efforts to thoroughly assess treatment efficacy, Cambridge Cognition has been contracted to deploy remote assessments of mood and cognition over a 12-month period. The assessments will be delivered on patients' mobile phones with their performance and wellbeing monitored by the pharmaceutical client.

The inclusion of remote and brief assessments during both the core and extension periods of the trial will provide the client with a better understanding of the relationships between mood, cognition and recovery. Cambridge Cognition is in a unique position to support the delivery of this trial with expertise in both gold-standard cognitive assessment and innovative digital health solutions for frequent, remote testing.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

" We are excited to be working with another pharmaceutical company that recognises the importance of frequent objective cognitive assessments in the development of treatments for central nervous system disorders. This new contract further validates the Company's strategy as again we will be configuring existing digital health solutions rather than undertaking bespoke software development. It also further highlights the opportunity available to Cambridge Cognition to provide remote, patient-centred solutions in the CNS market."

For further information, contact:

 
 Cambridge Cognition Holdings PLC              Tel: 012 2381 0700 
  Matthew Stork, Chief Executive Officer        press@camcog.com 
  Nick Walters, Chief Financial Officer 
 finnCap Ltd (NOMAD and Joint Broker)          Tel: 020 7220 0500 
  Geoff Nash / Simon Hicks                      (Corporate Finance) 
  Alice Lane / Sunila de Silva                  (Corporate Broking) 
 Dowgate Capital Limited (Joint Broker)        Tel: 020 3903 7715 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)        Tel: 020 3934 6630 
  Tim Metcalfe / Graham Herring / Zach Cohen 
 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABLBDDRUDDGGG

(END) Dow Jones Newswires

December 21, 2020 02:00 ET (07:00 GMT)

1 Year Cambridge Cognition Chart

1 Year Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

1 Month Cambridge Cognition Chart

Your Recent History

Delayed Upgrade Clock